picrotoxin has been researched along with Down Syndrome in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Barker, S; Costa, ACS; Faber, J; Pinheiro, DJLL; Scorza, CA; Scott-McKean, JJ; Stasko, MR; Victorino, DB | 1 |
| Costa, ACS; Johnson, MW; Roque, AL; Scott-McKean, JJ; Surewicz, K; Surewicz, WK | 1 |
| Underwood, E | 1 |
| Belichenko, PV; Epstein, CJ; Kleschevnikov, AM; Malenka, RC; Mobley, WC; Villar, AJ | 1 |
| Costa, AC; Grybko, MJ | 1 |
| Blank, M; Fernandez, F; Garner, CC; Malenka, RC; Morishita, W; Nguyen, J; Zuniga, E | 1 |
| Buckley, F; Sacks, B | 1 |
7 other study(ies) available for picrotoxin and Down Syndrome
| Article | Year |
|---|---|
Atypical electrophysiological and behavioral responses to diazepam in a leading mouse model of Down syndrome.
Topics: Animals; Diazepam; Disease Models, Animal; Down Syndrome; Electrophysiological Phenomena; Female; Long-Term Potentiation; Male; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Picrotoxin; Seizures; Synaptic Transmission | 2021 |
Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome.
Topics: Amyloid beta-Peptides; Animals; CA1 Region, Hippocampal; Disease Models, Animal; Down Syndrome; Electric Stimulation; Excitatory Amino Acid Antagonists; Female; Humans; Long-Term Potentiation; Male; Memantine; Mice, Inbred C57BL; Mice, Transgenic; Picrotoxin; Prion Proteins | 2018 |
Can Down syndrome be treated?
Topics: Adult; Animals; Brain; Child; Chromosomes, Human, Pair 21; Clinical Trials as Topic; Cognition Disorders; Down Syndrome; Early Medical Intervention; Female; GABA Antagonists; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Imaging; Male; Mice; Mutagenesis, Insertional; Picrotoxin; RNA, Long Noncoding | 2014 |
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.
Topics: 2-Amino-5-phosphonovalerate; Animals; Cognition Disorders; Crosses, Genetic; Dentate Gyrus; Disease Models, Animal; Down Syndrome; Evoked Potentials; Female; GABA-A Receptor Antagonists; Gene Dosage; Glycine; Hippocampus; Long-Term Potentiation; Magnesium; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Mutant Strains; Patch-Clamp Techniques; Picrotoxin; Presynaptic Terminals; Quinoxalines; Receptors, N-Methyl-D-Aspartate; Species Specificity; Trisomy | 2004 |
Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome.
Topics: Animals; Disease Models, Animal; Down Syndrome; Electric Stimulation; Excitatory Postsynaptic Potentials; GABA Antagonists; Hippocampus; Long-Term Potentiation; Male; Mice; Organ Culture Techniques; Picrotoxin; Synaptic Transmission | 2005 |
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.
Topics: Animals; Behavior, Animal; Cognition Disorders; Disease Models, Animal; Down Syndrome; Electric Stimulation; Excitatory Postsynaptic Potentials; Exploratory Behavior; Female; GABA Antagonists; Hippocampus; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Neurons; Pentylenetetrazole; Picrotoxin | 2007 |
Drug treatment improves memory in mice.
Topics: Animals; Central Nervous System Stimulants; Chromosomes, Human, Pair 21; Cyclopentanes; Disease Models, Animal; Down Syndrome; Furans; GABA Antagonists; Ginkgolides; Humans; Maze Learning; Memory; Mice; Mice, Transgenic; Neuropsychological Tests; Pentylenetetrazole; Picrotoxin | 2007 |